Functional characterization of novel germline TP53 variants in Swedish families

被引:10
|
作者
Kharaziha, Pedram [1 ]
Ceder, Sophia [1 ]
Axell, Olga [1 ]
Krall, Moritz [1 ]
Fotouhi, Omid [1 ]
Bohm, Stefanie [1 ]
Lain, Sonia [2 ]
Borg, Ake [3 ]
Larsson, Catharina [1 ]
Wiman, Klas G. [1 ]
Tham, Emma [4 ,5 ]
Bajalica-Lagercrantz, Svetlana [1 ,5 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, BioClinicum J6-20, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden
[3] Lund Univ, Div Oncol Pathol, Lund, Sweden
[4] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[5] Karolinska Univ Hosp, Dept Clin Genet, Stockholm, Sweden
关键词
germline TP53 mutation; hereditary breast cancer; Li-Fraumeni syndrome; p53; activity; LI-FRAUMENI SYNDROME; ONSET BREAST-CANCER; MUTANT P53; MUTATION CARRIERS; IMAGING SURVEILLANCE; RISK; BINDING; BRCA2;
D O I
10.1111/cge.13564
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Pathogenic germline TP53 variants predispose to a wide range of early onset cancers, often recognized as the Li-Fraumeni syndrome (LFS). They are also identified in 1% of families with hereditary breast cancer (HrBC) that do not fulfill the criteria for LFS. In this study, we present a total of 24 different TP53 variants identified in 31 Swedish families with LFS or HrBC. Ten of these variants, nine exonic and one splice, have previously not been described as germline pathogenic variants. The nine exonic variants were functionally characterized and demonstrated partial transactivation activity compared to wild-type p53. Some show nuclear localization similar to wild-type p53 while others possess cytoplasmic or perinuclear localization. The four frameshift variants (W91Gfs*32, L111 Wfs*12, S227 Lfs*20 and S240Kfs*25) had negligible, while F134 L and T231del had low level of p53 activity. The L111 Wfs*12 and T231del variants are also deficient for induction of apoptosis. The missense variant R110C retain p53 effects and the nonsense E349* shows at least partial transcription factor activity but has reduced ability to trigger apoptosis. This is the first functional characterization of novel germline TP53 pathogenic or likely pathogenic variants in the Swedish cohort as an attempt to understand its association with LFS and HrBC, respectively.
引用
收藏
页码:216 / 225
页数:10
相关论文
共 50 条
  • [31] Risk of therapy-related subsequent cancers in individuals with germline TP53 variants
    Villani, Anita
    Khincha, Payal
    Hatton, Jessica
    Schonfeld, Sara
    Goudie, Catherine
    Oba, Leatrisse
    Pithadia, Kishan
    Sanger, Birte
    Kratz, Christian
    Le, Anh N.
    Orr, Caitlin
    Maxwell, Kara N.
    Naumer, Anne
    Vagher, Jennie
    Kohlmann, Wendy
    Schi, Joshua
    dos Santos, Elizabeth Santana
    Michaeli, Orli
    Carson, Jacob J.
    Tsang, Derek S.
    Kim, Raymond
    Maciaszek, Jamie L.
    Nichols, Kim E.
    Goodman, Victoria E.
    MacFarland, Suzanne P.
    Reichman, Lara
    Achatz, Maria Isabel
    Savage, Sharon
    Malkin, David
    Morton, Lindsay M.
    CANCER RESEARCH, 2024, 84 (17)
  • [32] A NOVEL GERMLINE TP53 MUTATION IN A PATIENT WITH LI-FRAUMENI SYNDROME
    Douglass, David
    Farrar, Jason
    Stine, Kimo
    PEDIATRIC BLOOD & CANCER, 2019, 66
  • [33] A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families
    Patricia Llovet
    Francisco J. Illana
    Lorena Martín-Morales
    Miguel de la Hoya
    Pilar Garre
    M. Dolores Ibañez-Royo
    Pedro Pérez-Segura
    Trinidad Caldés
    Vanesa García-Barberán
    Familial Cancer, 2017, 16 : 567 - 575
  • [34] A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families
    Llovet, Patricia
    Illana, Francisco J.
    Martin-Morales, Lorena
    de la Hoya, Miguel
    Garre, Pilar
    Dolores Ibanez-Royo, M.
    Perez-Segura, Pedro
    Caldes, Trinidad
    Garcia-Barberan, Vanesa
    FAMILIAL CANCER, 2017, 16 (04) : 567 - 575
  • [35] Patterns of structural variants within TP53 introns and relocation of the TP53 promoter: a commentary
    Beird, Hannah C.
    Lin, Dimitri
    Lazar, Alexander J.
    Futreal, P. Andrew
    JOURNAL OF PATHOLOGY, 2024, 263 (02): : 131 - 134
  • [37] Information and prevention needs among germline TP53(gTP53m)pathogenic variants carriers
    Ben Ahmed, Tarek
    Vidican, Pauline
    Corradini, Nadege
    Lasset, Christine
    Goldbarg, Veronica
    Guerrini-Rousseau, Lea
    Claret, Beatrivr
    Fervers, Beatrice
    Rochefort, Pauline
    Delaloge, Suzette
    Caron, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Anaplastic Rhabdomyosarcoma in TP53 Germline Mutation Carriers
    Hettmer, Simone
    Archer, Natasha M.
    Somers, Gino R.
    Novokmet, Ana
    Wagers, Amy J.
    Diller, Lisa
    Rodriguez-Galindo, Carlos
    Teot, Lisa A.
    Malkin, David
    CANCER, 2014, 120 (07) : 1068 - 1075
  • [39] TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
    Grill, Sabine
    Ramser, Juliane
    Hellebrand, Heide
    Pfarr, Nicole
    Boxberg, Melanie
    Brambs, Christine
    Ditsch, Nina
    Meindl, Alfons
    Gross, Eva
    Meitinger, Thomas
    Kiechle, Marion
    Quante, Anne S.
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 303 (06) : 1557 - 1567
  • [40] TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
    Sabine Grill
    Juliane Ramser
    Heide Hellebrand
    Nicole Pfarr
    Melanie Boxberg
    Christine Brambs
    Nina Ditsch
    Alfons Meindl
    Eva Groß
    Thomas Meitinger
    Marion Kiechle
    Anne S. Quante
    Archives of Gynecology and Obstetrics, 2021, 303 : 1557 - 1567